Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Total Current Liabilities (2016 - 2025)

Dexcom (DXCM) has disclosed Total Current Liabilities for 15 consecutive years, with $2.9 billion as the latest value for Q4 2024.

  • On a quarterly basis, Total Current Liabilities rose 88.43% to $2.9 billion in Q4 2024 year-over-year; TTM through Dec 2024 was $2.9 billion, a 88.43% increase, with the full-year FY2024 number at $2.9 billion, up 88.43% from a year prior.
  • Total Current Liabilities was $2.9 billion for Q4 2024 at Dexcom, up from $1.6 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $2.9 billion in Q4 2024 to a low of $604.1 million in Q1 2021.
  • A 5-year average of $1.4 billion and a median of $1.2 billion in 2022 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 156.47% in 2023; the steepest drop was 15.4% in 2023.
  • Dexcom's Total Current Liabilities stood at $614.1 million in 2020, then grew by 17.38% to $720.8 million in 2021, then surged by 155.17% to $1.8 billion in 2022, then fell by 15.4% to $1.6 billion in 2023, then surged by 88.43% to $2.9 billion in 2024.
  • Per Business Quant, the three most recent readings for DXCM's Total Current Liabilities are $2.9 billion (Q4 2024), $1.6 billion (Q1 2024), and $1.6 billion (Q4 2023).